Aytu BioPharma details Investor Day materials
Aytu BioPharma, Inc. filed a current report describing investor communications held on January 20, 2026.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Aytu BioPharma, Inc. filed a current report describing investor communications held on January 20, 2026. The company issued a press release titled “Aytu BioPharma Recaps Investor Day Held on January 20, 2026,” which is furnished as an exhibit. Aytu also posted an investor presentation on its website used in an investor meeting that same day.
The presentation, attached as another exhibit, includes information about the EXXUA™ (gepirone) extended-release tablets opportunity, giving investors additional detail on this product. Both the press release and the presentation are furnished, not filed, meaning they are not automatically incorporated into other securities law filings unless specifically referenced.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Aytu BioPharma (AYTU) disclose in this Form 8-K?
Aytu BioPharma disclosed that it issued a press release recapping an Investor Day held on January 20, 2026, and furnished an investor presentation used at that meeting as exhibits to the report.
What exhibits are attached to Aytu BioPharma’s 8-K for January 20, 2026?
Exhibit 99.1 is a press release dated January 20, 2026, and Exhibit 99.2 is an Investor Day presentation dated January 20, 2026. Exhibit 104 is the cover page interactive data file.
What product information is highlighted in Aytu BioPharma’s investor presentation?
The investor presentation includes information on the EXXUA™ (gepirone) extended-release tablets opportunity, providing additional detail on this product for investors.
Are the Aytu BioPharma press release and presentation considered filed with the SEC?
The press release in Exhibit 99.1 and the presentation in Exhibit 99.2 are furnished, not filed, and are not deemed incorporated by reference into other securities law filings unless specifically referenced.
Where can investors view Aytu BioPharma’s Investor Day presentation?
Investors can view the presentation on Aytu BioPharma’s website at https://investors.aytubio.com/ under the Events & Presentations section.
Who signed Aytu BioPharma’s January 20, 2026 Form 8-K?
The Form 8-K was signed on behalf of Aytu BioPharma, Inc. by Ryan J. Selhorn, the company’s Chief Financial Officer.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|
|
||
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
(Address of principal executive offices, including zip code)
(720 ) 437-6580
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of Each Class
|
Trading Symbol(s)
|
Name of Each Exchange on Which Registered
|
||
|
|
|
The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On January 20, 2026, Aytu BioPharma, Inc. (the “Company” or “Aytu”) issued a press release titled “Aytu BioPharma Recaps Investor Day Held on January 20, 2026.” A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
On January 20, 2026, the Company posted to its website a presentation that was used in connection with an investor meeting held on January 20, 2026. The presentation includes, among other matters, information on the EXXUA™ (gepirone) extended-release tablets opportunity. A copy of the presentation is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K. The presentation can also be viewed on the Company’s website at https://investors.aytubio.com/ under Events & Presentations.
The information in the press release attached as Exhibit 99.1 and the information in the presentation attached as Exhibit 99.2 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit Number
|
Exhibit Description
|
|
|
99.1
|
Press Release dated January 20, 2026
|
|
| 99.2 | Investor Day Presentation Dated January 20, 2026 | |
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AYTU BIOPHARMA, INC.
|
||
|
Date: January 20, 2026
|
By:
|
/s/ Ryan J. Selhorn
|
|
Ryan J. Selhorn
|
||
|
Chief Financial Officer
|
||